| Name: | Aprepitant Related Compound B |
| Catalogue No. | VL1110002 |
| CAS No. | 172822-29-6 |
| Molecular Formula | C23H21F7N4O3 |
| Molecular Weight | 534.43 |
| Status | In-stock |
| IUPAC Name | 3-[[(2R,3R)-2-[(R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluoro phenyl)morpholino]methyl]-1H-1,2,4-triazol-5(4H)-one |
| Synonyms | Aprepitant EP Impurity D |
| Description | Aprepitant Related Compound B (CAS NO.-172822-29-6) IUPAC Name-3-[[(2R,3R)-2-[(R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluoro phenyl)morpholino]methyl]-1H-1,2,4-triazol-5(4H)-one. Aprepitant belongs to the neurokinin NK1 receptor antagonists class of agents. it is given in combination with other agents in order to prevent acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy in adults. aprepitant (125mg day 1, 80mg days 2 and 3 |
| References | Dando, Toni M., and Caroline M. Perry. “Aprepitant.” Drugs, vol. 64, no. 7, 2004, pp. 777–94, https://doi.org/10.2165/00003495-200464070-00013. Curran, Monique P., and Dean M. Robinson. “Aprepitant.” Drugs, vol. 69, no. 13, Sept. 2009, pp. 1853–78, https://doi.org/10.2165/11203680-000000000-00000. |
